Key result
Irinotecan, oxaliplatin, and monoclonal antibodies are emerging as potential treatments for colon cancer, including as adjuvant therapy for Dukes's type C and in fluorouracil-resistant patients.
Population
Patients with colon cancer, including those resistant to fluorouracil and those with Dukes's type C colon…
Design
Editorial
Authors
Loading...
The treatment of colon cancer is rapidly advancing with the introduction of new agents like irinotecan, oxaliplatin, and monoclonal antibodies.
The treatment of colon cancer is rapidly advancing with the introduction of new agents like irinotecan, oxaliplatin, and monoclonal antibodies.
K Jennings (1996) conducted a review in Colon cancer. Irinotecan, oxaliplatin, and monoclonal antibodies was evaluated. Irinotecan, oxaliplatin, and monoclonal antibodies are emerging as potential treatments for colon cancer, including as adjuvant therapy for Dukes's type C and in fluorouracil-resistant patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: